FEATURED COMPANIES
- Abbott Laboratories
- Anika Therapeutics Inc.
- Bayer Aktiengesellschaft
- Eli Lilly and Company
- Flexion Therapeutics Inc.
- GlaxoSmithKline PLC
The global osteoarthritis therapeutics market reached a value of nearly US$ 8 Billion in 2020. Looking forward, the market is expected to grow at a CAGR of 8.4% during 2021-2026. Keeping in mind the uncertainties of COVID-19, the analyst is continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Osteoarthritis (OA) is a heterogeneous condition characterized by progressive degeneration of cartilage in joints of the knees, hips, hands, feet, spine, shoulders and neck. OA generally leads to stiffness, swelling, tenderness, persistent pain, loss of flexibility, grating sensation, bone spurs and sleep disturbances. It can be diagnosed using physical examination, X-ray, arthroscopy, joint fluid analysis, blood tests and magnetic resonance imaging (MRI) scan. Various medications and surgical procedures are prescribed as per the different results to alleviate the signs and symptoms of the disease. Currently, alternative medicines, physical therapies and supportive devices are available in the market to relieve pain and improve joint function.
Sedentary lifestyles, unhealthy dietary patterns and the rising prevalence of obesity and blood sugar are increasing the risk of developing OA among individuals. This, in confluence with the growing geriatric population, which is more susceptible to such ailments, represents one of the key factors impelling the osteoarthritis therapeutics market growth. Apart from this, the easy access to MRI scans is acting as another major growth-inducing factor. Additionally, the development of imaging biomarkers based on radiographic features, coupled with the introduction of analgesic drugs, is contributing to the market growth. Furthermore, rising investments in the research and development (R&D) activities to launch new diagnostics and biomarkers, along with the increasing expenditures on improving healthcare infrastructure, is also driving the market. For instance, disease-modifying drugs are under development, which focus on proinflammatory cytokines for treating cartilage breakdown.
The analyst provides an analysis of the key trends in each sub-segment of the global osteoarthritis therapeutics market, along with forecasts at the global, regional and country level from 2021-2026. The report has categorized the market based on region, anatomy type, drug type, route of administration and distribution channel.
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Anika Therapeutics Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Flexion Therapeutics Inc., GlaxoSmithKline Plc, Horizon Therapeutics Plc, Johnson & Johnson Inc., Pfizer Inc. and Sanofi S.A.
Osteoarthritis (OA) is a heterogeneous condition characterized by progressive degeneration of cartilage in joints of the knees, hips, hands, feet, spine, shoulders and neck. OA generally leads to stiffness, swelling, tenderness, persistent pain, loss of flexibility, grating sensation, bone spurs and sleep disturbances. It can be diagnosed using physical examination, X-ray, arthroscopy, joint fluid analysis, blood tests and magnetic resonance imaging (MRI) scan. Various medications and surgical procedures are prescribed as per the different results to alleviate the signs and symptoms of the disease. Currently, alternative medicines, physical therapies and supportive devices are available in the market to relieve pain and improve joint function.
Global Osteoarthritis Therapeutics Market Trends and Drivers
Sedentary lifestyles, unhealthy dietary patterns and the rising prevalence of obesity and blood sugar are increasing the risk of developing OA among individuals. This, in confluence with the growing geriatric population, which is more susceptible to such ailments, represents one of the key factors impelling the osteoarthritis therapeutics market growth. Apart from this, the easy access to MRI scans is acting as another major growth-inducing factor. Additionally, the development of imaging biomarkers based on radiographic features, coupled with the introduction of analgesic drugs, is contributing to the market growth. Furthermore, rising investments in the research and development (R&D) activities to launch new diagnostics and biomarkers, along with the increasing expenditures on improving healthcare infrastructure, is also driving the market. For instance, disease-modifying drugs are under development, which focus on proinflammatory cytokines for treating cartilage breakdown.
Key Market Segmentation
The analyst provides an analysis of the key trends in each sub-segment of the global osteoarthritis therapeutics market, along with forecasts at the global, regional and country level from 2021-2026. The report has categorized the market based on region, anatomy type, drug type, route of administration and distribution channel.
Breakup by Anatomy Type
- Knee
- Hip
- Hand
- Spine
- Others
Breakup by Drug Type
- Nonsteroidal Anti-Inflammatory Drugs
- Analgesics
- Corticosteroids
- Others
Breakup by Route of Administration
- Parenteral
- Topical
- Oral
Breakup by Distribution Channel
- Hospitals
- Specialty Clinics
- Medical Institutions
- Others
Breakup by Region
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Anika Therapeutics Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Flexion Therapeutics Inc., GlaxoSmithKline Plc, Horizon Therapeutics Plc, Johnson & Johnson Inc., Pfizer Inc. and Sanofi S.A.
Key Questions Answered in This Report
- How has the global osteoarthritis therapeutics market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global osteoarthritis therapeutics market?
- What are the key regional markets?
- What is the breakup of the market based on the anatomy type?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global osteoarthritis therapeutics market and who are the key players?
- What is the degree of competition in the industry?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Abbott Laboratories
- Anika Therapeutics Inc.
- Bayer Aktiengesellschaft
- Eli Lilly and Company
- Flexion Therapeutics Inc.
- GlaxoSmithKline PLC
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Osteoarthritis Therapeutics Market
6 Market Breakup by Anatomy Type
7 Market Breakup by Drug Type
8 Market Breakup by Route of Administration
9 Market Breakup by Distribution Channel
10 Market Breakup by Region
11 SWOT Analysis
13 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Note: Product cover images may vary from those shown
- Abbott Laboratories
- Anika Therapeutics Inc.
- Bayer Aktiengesellschaft
- Eli Lilly and Company
- Flexion Therapeutics Inc.
- GlaxoSmithKline PLC
- Horizon Therapeutics PLC
- Johnson & Johnson Inc.
- Pfizer Inc.
- Sanofi S.A.
Note: Product cover images may vary from those shown
LOADING...
